An adaptation of the diabetes prevention program for use with high-risk, minority patients with type 2 diabetes

被引:36
|
作者
Cramer, J. Steven
Sibley, Ralph F.
Bartlett, Donald P.
Kahn, Linda S.
Loffredo, Lisa
机构
[1] SUNY Buffalo, Sch Med & Biomed Sci, Dept Family Med, Tonawanda, NY 14150 USA
[2] Kaleida Hlth, Buffalo, NY USA
来源
DIABETES EDUCATOR | 2007年 / 33卷 / 03期
关键词
D O I
10.1177/0145721707301680
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE The purpose of this pilot study was to determine the effectiveness of an edited Diabetes Prevention Program (DPP) Lifestyle Resources Core Teaching Plan for managing patients with type 2 diabetes in an urban underserved setting. Modifications were made to attempt to cut to the bare essentials to work within the constrained budgets of safety net providers. The primary aim was to achieve a mean absolute reduction in HbA1c level of 1 percentage point. METHODS The authors conducted a randomized controlled trial of 9 months' duration for patients with type 2 diabetes with an HbA1c >= 8.0%. A total of 67 patients randomized into usual-care and case management groups were evaluated with an intention-to-treat analysis. A modified DPP workbook was used during 7 monthly visits with a nurse case manager. RESULTS As compared with the usual-care group, those in the case management group experienced a greater reduction in HbA1c level (-1.87 vs -0.54; P =.011) and weight (-2.47 kg vs +0.88 kg; P =.011). CONCLUSION Use of an edited version of the DPP workbook in an urban, low-income, minority population with type 2 diabetes produced a significant absolute reduction in HbA1c percentage and weight.
引用
收藏
页码:503 / 508
页数:6
相关论文
共 50 条
  • [21] Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients
    Freemark, M
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01): : 3 - 13
  • [22] Dalcetrapib in high-risk patients with type 2 diabetes mellitus and/or metabolic syndrome
    Stalenhoef, A. F. H.
    Davidson, M. H.
    Robinson, J. G.
    Duttlinger-Maddux, R.
    Kallend, D.
    Bays, H.
    DIABETOLOGIA, 2009, 52 : S487 - S487
  • [23] Rosiglitazone, but not ramipril, prevents onset of type 2 diabetes in high-risk patients
    不详
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 (1): : 6 - 6
  • [24] Why We Should Screen for Type 2 Diabetes in High-Risk Patients
    Kirkman, M. Sue
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2013, 44 (04) : S371 - S374
  • [25] Risk Factors for the Development of Retinopathy in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Experience
    White, Neil H.
    Pan, Qing
    Knowler, William C.
    Schroeder, Emily B.
    Dabelea, Dana
    Chew, Emily Y.
    Blodi, Barbara
    Goldberg, Ronald B.
    Pi-Sunyer, Xavier
    Darwin, Christine
    Schlogl, Mathias
    Nathan, David M.
    DIABETES CARE, 2022, 45 (11) : 2653 - 2661
  • [26] Development of a Yoga Program for Type-2 Diabetes Prevention (YOGA-DP) Among High-Risk People in India
    Chattopadhyay, Kaushik
    Mishra, Pallavi
    Manjunath, Nandi Krishnamurthy
    Harris, Tess
    Hamer, Mark
    Greenfield, Sheila Margaret
    Wang, Haiquan
    Singh, Kavita
    Lewis, Sarah Anne
    Tandon, Nikhil
    Kinra, Sanjay
    Prabhakaran, Dorairaj
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [27] Optimizing an mHealth Program to Promote Type 2 Diabetes Prevention in High-Risk Individuals: Cross-Sectional Questionnaire Study
    Ross, Edgar
    Al Ozairi, Ebaa
    Al Qabandi, Naeema
    Jamison, Robert
    JMIR FORMATIVE RESEARCH, 2023, 7
  • [28] Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects
    Standl, E
    DIABETES & METABOLISM, 2003, 29 (04) : S121 - S122
  • [29] Antidepressant Medication Use and Risk of Developing Diabetes during the Diabetes Prevention Program andthe Diabetes Prevention Program Outcomes Study
    Rubin, Richard R.
    Marrero, David G.
    Ma, Yong
    Knowler, William C.
    Price, David
    Barrett-Connor, Elizabeth
    Peyrot, Mark
    DIABETES, 2010, 59 : A128 - A129
  • [30] Prevalence and factors associated with statin use in high-risk patients with type 1 diabetes from a specialized diabetes unit
    Amor, Antonio J.
    Ortega, Emilio
    Gimenez, Marga
    Cofan, Montserrat
    Blanco, Jesus
    Pane, Adriana
    Boswell, Laura
    Vinagre, Irene
    Esmatjes, Enric
    Conget, Ignacio
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2019, 66 (08): : 512 - 519